HN1997000052A - Nuevas 4(3h)--quinazolinas 2,3-disustituidas - Google Patents

Nuevas 4(3h)--quinazolinas 2,3-disustituidas

Info

Publication number
HN1997000052A
HN1997000052A HN1997000052A HN1997000052A HN1997000052A HN 1997000052 A HN1997000052 A HN 1997000052A HN 1997000052 A HN1997000052 A HN 1997000052A HN 1997000052 A HN1997000052 A HN 1997000052A HN 1997000052 A HN1997000052 A HN 1997000052A
Authority
HN
Honduras
Prior art keywords
new
quinazolins
disstituted
salees
neurodegenerative
Prior art date
Application number
HN1997000052A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN1997000052A publication Critical patent/HN1997000052A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE LA FORMULA I DESCRITOS MAS ADELANTA, A SUS SALEES FARMACEUTICAMENTE ACEPTABLES, A COMPOSICINES FARMACEUTICAS Y A PROCEDIMIENTOS DE TRATAMIENTO DE AFECCIONES NEURODEGENERATIVAS Y RELACIONADAS CON TRAUMATISMO DEL SNC.
HN1997000052A 1996-05-15 1997-04-21 Nuevas 4(3h)--quinazolinas 2,3-disustituidas HN1997000052A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
HN1997000052A true HN1997000052A (es) 1997-06-26

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1997000052A HN1997000052A (es) 1996-05-15 1997-04-21 Nuevas 4(3h)--quinazolinas 2,3-disustituidas

Country Status (39)

Country Link
US (1) US6303615B1 (es)
EP (1) EP0901487B9 (es)
JP (1) JP3241388B2 (es)
KR (1) KR100375155B1 (es)
CN (2) CN1103772C (es)
AP (1) AP1148A (es)
AR (1) AR007118A1 (es)
AT (1) ATE242232T1 (es)
AU (1) AU730503B2 (es)
BG (1) BG102999A (es)
BR (1) BR9709085A (es)
CA (1) CA2252907C (es)
CZ (1) CZ295565B6 (es)
DE (1) DE69722613T2 (es)
DK (1) DK0901487T3 (es)
DZ (1) DZ2237A1 (es)
EA (1) EA002905B1 (es)
ES (1) ES2198546T3 (es)
GT (1) GT199700049A (es)
HK (1) HK1019607A1 (es)
HN (1) HN1997000052A (es)
HR (1) HRP970261B1 (es)
HU (1) HUP9902148A3 (es)
ID (1) ID17149A (es)
IL (1) IL126589A (es)
IS (1) IS4881A (es)
MA (1) MA26430A1 (es)
NO (1) NO985293L (es)
OA (1) OA10918A (es)
PL (1) PL330042A1 (es)
PT (1) PT901487E (es)
SI (1) SI0901487T1 (es)
SK (1) SK284108B6 (es)
TN (1) TNSN97087A1 (es)
TR (1) TR199802296T2 (es)
TW (1) TW539675B (es)
WO (1) WO1997043276A1 (es)
YU (1) YU19197A (es)
ZA (1) ZA974156B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248254A (zh) * 1997-02-28 2000-03-22 辉瑞产品公司 用于治疗神经变性疾病及与中枢神经***创伤相关疾病的3－杂芳基－4(3h)－喹唑啉酮的阻转异构体
EA001963B1 (ru) * 1997-02-28 2001-10-22 Пфайзер Продактс Инк. Атропизомеры 3-арил-4(3н)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
DE60027546T2 (de) 1999-02-15 2007-04-26 Eisai Co., Ltd. Heterodiazinon-derivate
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2177520A1 (en) 2000-06-12 2010-04-21 Eisai R&D Management Co., Ltd. 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors
US7053216B2 (en) 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2006501201A (ja) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JP2009514954A (ja) * 2005-11-04 2009-04-09 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能を変調するための化合物
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US8492395B2 (en) * 2007-09-26 2013-07-23 Celgene Corporation 7-substituted quinazolinone compounds and compositions comprising the same
EP2239257B1 (en) 2008-01-30 2012-06-06 Shin Poong Pharmaceutical Co. Ltd. Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP3427739A1 (en) 2008-11-13 2019-01-16 Gilead Calistoga LLC Therapies for hematologic malignancies
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
BR112012001325A2 (pt) 2009-07-21 2017-05-02 Gilead Calistoga Llc tratamento de distúrbios do fígado com inibidaores de pi3k
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
ES2752552T3 (es) 2013-12-20 2020-04-06 Gilead Calistoga Llc Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
BR112021010953A2 (pt) 2018-12-14 2021-08-24 Eisai R&D Management Co., Ltd. Formulações farmacêuticas de base aquosa de compostos de 1,2-di-hidropiridina
CN115335050A (zh) 2020-01-29 2022-11-11 卡玛瑞制药有限公司 用于治疗皮肤病症的化合物和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
DK0698024T3 (da) 1993-05-06 1997-07-28 Novo Nordisk As 1,2,4 triazolo 4,3-a quinoxalinforbindelser, deres fremstilling og anvendelse
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
EA001963B1 (ru) 1997-02-28 2001-10-22 Пфайзер Продактс Инк. Атропизомеры 3-арил-4(3н)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов

Also Published As

Publication number Publication date
HRP970261A2 (en) 2000-12-31
HRP970261B1 (en) 2003-06-30
DZ2237A1 (fr) 2002-12-03
SK284108B6 (sk) 2004-09-08
JP3241388B2 (ja) 2001-12-25
KR20000011054A (ko) 2000-02-25
HK1019607A1 (en) 2000-02-18
AU1554997A (en) 1997-12-05
PT901487E (pt) 2003-08-29
AP9701003A0 (en) 1997-07-31
BR9709085A (pt) 1999-08-03
HUP9902148A3 (en) 2002-11-28
TNSN97087A1 (fr) 2005-03-15
OA10918A (en) 2001-10-25
YU19197A (sh) 1999-09-27
TR199802296T2 (xx) 1999-02-22
SK152098A3 (en) 2000-05-16
CZ295565B6 (cs) 2005-08-17
TW539675B (en) 2003-07-01
IS4881A (is) 1998-10-27
DE69722613T2 (de) 2004-05-13
AU730503B2 (en) 2001-03-08
US6303615B1 (en) 2001-10-16
CN1420114A (zh) 2003-05-28
AR007118A1 (es) 1999-10-13
CZ352698A3 (cs) 1999-11-17
CN1218464A (zh) 1999-06-02
CA2252907C (en) 2005-05-17
JPH11514663A (ja) 1999-12-14
ES2198546T3 (es) 2004-02-01
ID17149A (id) 1997-12-04
MA26430A1 (fr) 2004-12-20
DK0901487T3 (da) 2003-08-25
IL126589A0 (en) 1999-08-17
WO1997043276A1 (en) 1997-11-20
IL126589A (en) 2003-06-24
EP0901487B9 (en) 2004-09-29
EA002905B1 (ru) 2002-10-31
EP0901487A1 (en) 1999-03-17
DE69722613D1 (de) 2003-07-10
BG102999A (en) 1999-09-30
AP1148A (en) 2003-02-28
SI0901487T1 (en) 2003-10-31
EP0901487B1 (en) 2003-06-04
CA2252907A1 (en) 1997-11-20
HUP9902148A2 (hu) 2000-04-28
NO985293L (no) 1999-01-13
EA199800923A1 (ru) 1999-06-24
ATE242232T1 (de) 2003-06-15
CN1103772C (zh) 2003-03-26
PL330042A1 (en) 1999-04-26
ZA974156B (en) 1998-11-16
NO985293D0 (no) 1998-11-13
KR100375155B1 (ko) 2003-08-19
GT199700049A (es) 1998-10-21

Similar Documents

Publication Publication Date Title
HN1997000052A (es) Nuevas 4(3h)--quinazolinas 2,3-disustituidas
HN1999000045A (es) Derivados biciclicos del acido hidroxamico
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
FI20115753A (fi) Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
PA8435001A1 (es) Derivados 6,6-heterobiciclicos sustituidos.
PT862424E (pt) Composicoes farmaceuticas compreendendo flurbiprofeno
DE69531790D1 (de) Duschaufsatz
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ES2176480T3 (es) Derivados acilados de la melatonina y de analogos como medicamentos.
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
MX9601994A (es) Profarmacos de derivados de paclitaxel.
SE9801494D0 (sv) Novel use
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
PA8446901A1 (es) Atropisomeros de 3-heteroaril-4(3h)-quinazolinonas
IT1318667B1 (it) Medicamento antinfiammatorio.
IS5366A (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
YU42098A (sh) Upotreba olanzapina
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
NO990450D0 (no) Behandling av sinnslidelser